Literature DB >> 30251576

L1CAM Immunopositivity in Anaplastic Supratentorial Ependymomas: Correlation With Clinical and Histological Parameters.

Pooja Chavali1, Shilpa Rao1, Sravya Palavalasa1, Nandeesh Bevinahalli1, Yasha T C Muthane1, Nishanth Sadashiva1, Vani Santosh1.   

Abstract

Supratentorial ependymomas (ST EPNs) are molecularly characterized, of which the RELA fusion positive tumors are the most common and aggressive subgroup. Moreover, histologically, anaplastic ST EPN (ST-AE) often mimic other central nervous system primary high-grade tumors resulting in a diagnostic dilemma. We aimed to study a cohort of ST-AE; evaluate the expression of two RELA fusion-associated markers-L1CAM and p65 (NF-κB); and correlate their expression with clinical and histological parameters. Cases of ST-AE diagnosed in our department from January 2011 to June 2016 (n = 72) were reviewed. A battery of immunohistochemical markers was employed. A total of 65 confirmed ST-AE were included in the study. Age ranged from 9 months to 60 years. There was a slight predominance in the pediatric population (57%). Male-to-female ratio was 1:1.16. Histomorphological features were varied and mimicked other high-grade tumors in several cases. L1CAM immunopositive tumors constituted 26% of cases and were predominantly seen in young children, in the frontoparietal location, and exhibited clear cell morphology with calcification. A consistent pattern of L1CAM immunopositivity was noted in paired primary and recurrent tumor samples. Our study portrays the varied clinical and histomorphological spectrum of ST-AE. The study emphasizes the association of L1CAM immunopositivity with a wide spectrum of histological parameters, literature on which is scant till date. Since ST EPN-RELA are tumors with aggressive behavior, such a correlation would be clinically relevant, particularly when there is limited access to molecular testing.

Entities:  

Keywords:  L1CAM; RELA fusion; histomorphological spectrum; p65; supratentorial anaplastic ependymoma

Mesh:

Substances:

Year:  2018        PMID: 30251576     DOI: 10.1177/1066896918800812

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  4 in total

Review 1.  Central nervous system ependymoma: clinical implications of the new molecular classification, treatment guidelines and controversial issues.

Authors:  P D Delgado-López; E M Corrales-García; E Alonso-García; R García-Leal; R González-Rodrigálvarez; E Araus-Galdós; J Martín-Alonso
Journal:  Clin Transl Oncol       Date:  2019-03-13       Impact factor: 3.405

Review 2.  Updates in the classification of ependymal neoplasms: The 2021 WHO Classification and beyond.

Authors:  Catena Kresbach; Sina Neyazi; Ulrich Schüller
Journal:  Brain Pathol       Date:  2022-03-21       Impact factor: 7.611

3.  Intracytoplasmic dot-like inclusions as cytopathologically useful findings of ependymoma: Case report of adolescent supratentorial anaplastic ependymoma with clear cell morphology.

Authors:  Taku Homma; Reina Mizuno; Yu Miyama; Tomonari Suzuki; Eita Uchida; Jun-Ichi Adachi; Masanori Yasuda
Journal:  Clin Case Rep       Date:  2020-11-16

4.  Ependymoma Pediatric Brain Tumor Protein Fingerprinting by Integrated Mass Spectrometry Platforms: A Pilot Investigation.

Authors:  Diana Valeria Rossetti; Luca Massimi; Claudia Martelli; Federica Vincenzoni; Susanna Di Silvestre; Gianluca Scorpio; Gianpiero Tamburrini; Massimo Caldarelli; Andrea Urbani; Claudia Desiderio
Journal:  Cancers (Basel)       Date:  2020-03-13       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.